Lyell Immunopharma, Inc.
General ticker "LYEL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $246.0M (TTM average)
Lyell Immunopharma, Inc. follows the US Stock Market performance with the rate: 0.1%.
Estimated limits based on current volatility of 6.8%: low 14.12$, high 16.19$
Factors to consider:
- Total employees count: 300 (+33.9%) as of 2024
- Top business risk factors: High losses and need for capital, Regulatory and compliance, Limited operating history, Market competition, Manufacturing complexity
- Current price 10.5% below estimated low
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [17.14$, 48.06$]
- 2026-12-31 to 2027-12-31 estimated range: [9.50$, 28.61$]
Financial Metrics affecting the LYEL estimates:
- Negative: with PPE of -2.2 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -24.89 <= 0.30
- Positive: Investing cash flow per share per price, % of 8.98 > -0.65
- Negative: negative Net income
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
- Negative: negative Industry operating cash flow (median)
Short-term LYEL quotes
Long-term LYEL plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.13MM | $0.06MM | $2.18MM |
| Operating Expenses | $247.14MM | $358.82MM | $271.58MM |
| Operating Income | $-247.01MM | $-358.75MM | $-269.40MM |
| Non-Operating Income | $12.38MM | $15.76MM | $-5.04MM |
| R&D Expense | $182.94MM | $171.60MM | $158.68MM |
| Income(Loss) | $-234.63MM | $-342.99MM | $-274.45MM |
| Net Income(Loss)* | $-234.63MM | $-342.99MM | $-274.45MM |
| Stockholders Equity | $654.95MM | $382.82MM | $248.20MM |
| Assets | $750.03MM | $490.86MM | $340.05MM |
| Operating Cash Flow | $-163.69MM | $-162.39MM | $-150.02MM |
| Capital expenditure | $2.69MM | $0.46MM | $0.78MM |
| Investing Cash Flow | $184.05MM | $122.42MM | $54.10MM |
| Financing Cash Flow | $1.74MM | $1.33MM | $50.41MM |
| Earnings Per Share** | $-18.70 | $-26.23 | $-16.06 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.